This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

John A. Bartlett, MD

JAMA. 1988;260(20):3051-3052.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Between 1 and 2 million Americans are infected with the human immunodeficiency virus (HIV).¹ Available evidence suggests that most, if not all, will ultimately develop the acquired immunodeficiency syndrome (AIDS) within a projected mean of eight years after HIV acquistion.² Clearly, the need is great for HIV-directed therapy. Due to the ability of HIV to establish latent infection within cells, therapy must be considered as lifelong in duration with a "cure" unlikely in the near future. Therefore, the goals of therapy for now must be to improve the quality and quantity of life for persons with AIDS and to prevent disease progression in persons with AIDS-related complex (ARC) and asymptomatic HIV infection. Potential therapeutic agents for HIV infection must surmount major hurdles, including control of latent virus infection, central nervous system penetration, and the rapid development of viral variants. These agents are then administered to persons with ARC . . . [Full Text PDF of this Article]

Author Affiliations
Duke University Medical Center Durham, NC

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?